Not FDA cleared.
Not available in the United States.
HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device is a new resting 12-lead electrocardiograph. It uses continuous wavelet transform (CWT) signal processing to provide new frequency and energy information to detect cardiac relaxation abnormalities associated with left ventricular diastolic dysfunction (LVDD). Extensive research confirms that almost all forms and co-morbidities of heart disease are associated with LVDD including hypertension, diabetes, valvular disease, ischemia, and reduced systolic function.
The MyoVista wavECG Device is an innovative advancement for low-cost electrocardiographic testing designed to provide physicians with new information to improve patient risk-assessment related to heart disease. This additional risk stratification information assists physicians in determining whether a patient should receive further testing, evaluation and/or treatment. In addition to wavECG Information, the MyoVista Device also provides all the information and capabilities of a full-featured conventional resting 12-lead ECG within the same test, at comparable cost, and following the same clinical AHA/IEC lead placement protocol.